摘要
原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见的高度侵袭性结外非霍奇金淋巴瘤,其治疗效果及患者生存预后情况目前仍不令人满意。近年来国内外研究团队正致力于从临床常用的血液学指标以及相关基因、蛋白等中寻找到能更有效地预测PCNSL预后的指标,以期在临床上更精准地指导PCNSL诊疗、更大程度地改善PCNSL患者预后。笔者现通过检索PubMed数据库,就目前相关PCNSL预后指标的研究报道进行回顾性总结。
Primary central nervous system lymphoma(PCNSL)is a kind of highly aggressive and rare extranodal non-Hodgkin lymphoma,and the treatment effect and survival prognosis of these patients are still not satisfied.In recent years,domestic and foreign researchers have devoted themselves to find more effective prognostic indicators from clinical hematological indicators,as well as gene and protein levels,so as to guide the diagnosis and treatment of PCNSL more accurately in clinical practice and improve the prognosis of PCNSL patients to a greater extent.This paper provides a review of such studies by reviewing PubMed.
作者
高玉婷
刘伯杨
游华
Gao Yuting;Liu Boyang;You Hua(Internal Medicine Department III,Affiliated Cancer Hospital of Guangzhou Medical University,Guangzhou 510095,China;National Key Clinical Specialty,Engineering and Technology Research Center of Ministry of Education,Guangdong Provincial Key Laboratory of Brain Function Repair and Regeneration,Guangdong Institute of Neurosurgery,Department of Neurosurgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510282,China)
出处
《中华神经医学杂志》
CAS
CSCD
北大核心
2022年第8期831-836,共6页
Chinese Journal of Neuromedicine
基金
国家自然科学基金(81911530169、81903088、81670180)。
